NCT05918107

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

Phase II Clinical Trial to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetic Characteristics of PM8002 Injection Combined With Standard Chemotherapy in the First-line Treatment of Subjects With Inoperable Malignant Mesothelioma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 55 (estimated)
• Sponsor: Biotheus Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with pemetrexed and platinum as first line treatment for MPM.

Detailed description

PD-L1 and VEGF play important roles in immune escape and tumor angiogenesis and enhance cancer growth and metastasis. PM8002 is a bispecific antibody targeting PD-L1 and VEGF-A. Here, the investigators present the results from a Phase II study of PM8002 in combination with pemetrexed and platinum subjects in unresectable malignant mesothelioma.

Conditions

• MPM

Interventions

Type	Name	Description
DRUG	PM8002	IV infusion
DRUG	Pemetrexed	IV infusion
DRUG	Cisplatin	IV infusion
DRUG	Carboplatin	IV infusion

Timeline

• Start date: 2022-08-13
• Primary completion: 2026-06-30
• Completion: 2026-06-30
• First posted: 2023-06-26
• Last updated: 2023-06-27

Locations

1 site across 1 country: China